GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Cash Conversion Cycle

Xtant Medical Holdings (Xtant Medical Holdings) Cash Conversion Cycle : 309.29 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Xtant Medical Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 64.73.
Xtant Medical Holdings's Days Inventory for the three months ended in Dec. 2023 was 296.18.
Xtant Medical Holdings's Days Payable for the three months ended in Dec. 2023 was 51.62.
Therefore, Xtant Medical Holdings's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 309.29.


Xtant Medical Holdings Cash Conversion Cycle Historical Data

The historical data trend for Xtant Medical Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Cash Conversion Cycle Chart

Xtant Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 260.52 370.04 317.15 262.46 285.30

Xtant Medical Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 238.78 235.85 239.91 271.49 309.29

Competitive Comparison of Xtant Medical Holdings's Cash Conversion Cycle

For the Medical Devices subindustry, Xtant Medical Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Cash Conversion Cycle falls into.



Xtant Medical Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Xtant Medical Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=63.13+275.87-53.7
=285.30

Xtant Medical Holdings's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=64.73+296.18-51.62
=309.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings  (AMEX:XTNT) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Xtant Medical Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Executives
Kevin D Brandt officer: VP & Chief Commercial Officer 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller director 664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson director 664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils officer: Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger officer: Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne officer: President and CEO 664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis director 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen officer: VP, Finance and Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin officer: VP & Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen officer: SVP Fiance & Admin. & CFO 664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750

Xtant Medical Holdings (Xtant Medical Holdings) Headlines

From GuruFocus